Meningitis is an infection of the meninges, the membranes surrounding the brain and spinal cord. It can be caused by a number of different viral and bacterial pathogens including Haemophilus influenzae b (Hib) and Streptococcus pneumoniae. However, in the US, Neisseria meningitidis is the most common cause of bacterial meningitis in infants and young children, as well as one of the most important causes in adults. There are 13 known serotypes of meningococcal disease, of which five (A, B, C, Y, and W-135) account for 90% of the global disease burden.
MARKET SNAPSHOT
- Continued uptake of MenB vaccines and GlaxoSmithKline’s pentavalent vaccine launch from 2021 will drive market growth.
- Cost-effectiveness concerns and scarcity of real-world effectiveness data are key resistors of uptake for MenB vaccines.
- Pipeline vaccines with broader serotype protection and novel approaches are positioned to replace marketed products.
CONTENTS
6 FORECAST: MENINGOCOCCAL VACCINES (Published on 03 September 2019)
6 OVERVIEW
7 RECENT FORECAST UPDATES
8 MARKET DYNAMICS
11 FORECASTS AND FUTURE TRENDS
15 US MARKET FORECAST
18 FRANCE MARKET FORECAST
21 GERMANY MARKET FORECAST
24 ITALY MARKET FORECAST
27 SPAIN MARKET FORECAST
30 UK MARKET FORECAST
33 MARKET DEFINITION AND METHODOLOGY
38 PRIMARY RESEARCH METHODOLOGY
40 BIBLIOGRAPHY
42 MARKETED DRUGS: MENINGOCOCCAL VACCINES (Published on 03 September 2019)
42 OVERVIEW
43 PRODUCT OVERVIEW
44 PRODUCT PROFILE: BEXSERO
52 PRODUCT PROFILE: MENACTRA
59 PRODUCT PROFILE: MENVEO
66 PRODUCT PROFILE: NIMENRIX
74 PRODUCT PROFILE: TRUMENBA
82 PIPELINE: MENINGOCOCCAL VACCINES (Published on 03 September 2019)
82 OVERVIEW
83 CLINICAL PIPELINE OVERVIEW
84 ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
85 PRODUCT PROFILE (LATE STAGE): MENABCW-135Y
92 PRODUCT PROFILE (LATE STAGE): MENQUADFI
LIST OF FIGURES
12 Figure 1: Meningococcal vaccines total market value across the US and five major EU markets, by country, 2018−27
13 Figure 2: Meningococcal vaccine sales in the US, 2018–27
14 Figure 3: Meningococcal vaccine sales in the five major EU markets, by country, 2018–27
16 Figure 4: Total sales of meningococcal vaccines in the US, by class, 2018–27
17 Figure 5: Meningococcal vaccination coverage in the US, by risk group, 2018–27
19 Figure 6: Total sales of meningococcal vaccines in France, by class, 2018–27
20 Figure 7: Meningococcal vaccination coverage in France, by risk group, 2018–27
22 Figure 8: Total sales of meningococcal vaccines in Germany, by class, 2018–27
23 Figure 9: Meningococcal vaccination coverage in Germany, by risk group, 2018–27
25 Figure 10: Total sales of meningococcal vaccines in Italy, by class, 2018–27
26 Figure 11: Meningococcal vaccination coverage in Italy, by risk group, 2018–27
28 Figure 12: Total sales of meningococcal vaccines in Spain, by class, 2018–27
29 Figure 13: Meningococcal vaccination coverage in Spain, by risk group, 2018–27
31 Figure 14: Total sales of meningococcal vaccines in the UK, by class, 2018–27
32 Figure 15: Meningococcal vaccination coverage in the UK, by risk group, 2018–27
34 Figure 16: Patient-based forecasting methodology for meningococcal vaccines
36 Figure 17: Price sources and calculations, by country
LIST OF TABLES
7 Table 1: Recent events incorporated into the meningococcal vaccination forecast
9 Table 2: Meningococcal vaccination – current and future market dynamics analysis
10 Table 3: Recommendations for meningococcal vaccination by national authorities, 2019
11 Table 4: Meningococcal vaccines – current and future forecast trends
15 Table 5: Meningococcal vaccines – current and future forecast trends in the US
18 Table 6: Meningococcal vaccines – current and future forecast trends in France
21 Table 7: Meningococcal vaccines – current and future forecast trends in Germany
24 Table 8: Meningococcal vaccines – current and future forecast trends in Italy
27 Table 9: Meningococcal vaccines – current and future forecast trends in Spain
30 Table 10: Meningococcal vaccines – current and future forecast trends in the UK
37 Table 11: Exchange rates used for calculating prices
39 Table 12: Therapies discussed in the primary research for meningococcal vaccines
43 Table 13: Profiled key marketed vaccines for meningococcal disease
45 Table 14: Bexsero drug profile
46 Table 15: Approval history of Bexsero for meningococcal vaccination in the US and five major EU markets
47 Table 16: Late-phase trials of Bexsero for meningococcal vaccination
48 Table 17: Bexsero for meningococcal disease – SWOT analysis
53 Table 18: Menactra drug profile54 Table 19: Approval history of Menactra for meningococcal vaccination in the US and Japan
55 Table 20: Late-phase trials of Menactra for meningococcal vaccination
56 Table 21: Menactra for meningococcal disease – SWOT analysis
60 Table 22: Menveo drug profile
61 Table 23: Approval history of Menveo for meningococcal vaccination in the US and five major EU markets
62 Table 24: Late-phase trials of Menveo for meningococcal vaccination
63 Table 25: Menveo for meningococcal disease – SWOT analysis
67 Table 26: Nimenrix drug profile
68 Table 27: Approval history of Nimenrix for meningococcal vaccination in the five major EU markets
69 Table 28: Late-phase trials of Nimenrix for meningococcal vaccination
71 Table 29: Nimenrix for meningococcal disease – SWOT analysis
75 Table 30: Trumenba drug profile
76 Table 31: Approval history of Trumenba for meningococcal vaccination in the US and five major EU markets
77 Table 32: Late-phase trials of Trumenba for meningococcal vaccination
78 Table 33: Trumenba for meningococcal disease – SWOT analysis
83 Table 34: Profiled pipeline products in development for meningococcal vaccination
86 Table 35: MenABCW-135Y drug profile
87 Table 36: Late-phase trials of MenABCW-135Y for meningococcal vaccination
89 Table 37: MenABCW-135Y for meningococcal disease – SWOT analysis
93 Table 38: MenQuadfi drug profile
95 Table 39: Late-phase trials of MenQuadfi for meningococcal vaccination
97 Table 40: MenQuadfi for meningococcal vaccination – SWOT analysis
Sign up to the